Polypeptide-Oligonucleotide Conjugates for ChIP Assay Validation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chromatin immunoprecipitation (ChIP) assays lack effective control agents for validating results and distinguishing between true and false positives/negatives, particularly for histone modifications and non-histone proteins, due to limitations in specificity and the need for species-specific controls.
Innovation Solution
Development of polypeptide-oligonucleotide conjugates comprising a polypeptide segment with an antigen and an oligonucleotide segment with a unique sequence, linked by a linker, which can be used as control agents in ChIP assays to validate results and normalize data, applicable to various histone modifications and non-histone proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional ChIP assays are performed without specific control agents, then the assay can be conducted with standard antibodies, but the ability to validate results and distinguish true positives from false positives is insufficient
Solution Approach 1:
The patent introduces control agents as intermediary substances that mediate between the antibody and the detection system. These control agents contain known epitopes linked to identifiable markers, serving as a bridge to validate antibody performance and distinguish specific from non-specific binding events in ChIP assays
Solution Approach 2:
The control agents are designed as simplified copies or models of the actual target proteins, containing specific epitopes that mimic the structure and antigenic properties of native histone or non-histone proteins. This allows validation of antibody specificity without requiring the complex native protein structure
2Measurement precision
If species-specific control agents are used for each ChIP assay, then the specificity for particular species and targets is improved, but the complexity of selecting and preparing appropriate controls increases
Solution Approach 1:
The control agents are designed with universal components including common epitope sequences, standardized linker structures, and versatile oligonucleotide tags that can be detected by multiple methods. This multi-functionality allows a single control agent to serve validation purposes across different species and experimental conditions, reducing the need for multiple specialized controls
3Reliability
If control agents with unique identifiers are used for normalization, then data normalization capability is improved, but the manufacturing complexity of producing these conjugates increases
Solution Approach 1:
The control agent is divided into separate functional segments including the epitope-containing polypeptide portion, the linker molecule, and the oligonucleotide identifier. This segmentation allows each component to be produced and purified independently using standard biochemical methods, then combined through conjugation chemistry, simplifying the overall manufacturing process compared to producing complete complex conjugates in a single step
Data Source
AI summary
Control agents for immuno-precipitation assays, methods of using the control agents and kits comprising the control agents are provided.